CLINIAL’s blog on “note” now features an article exploring “Drug Loss 2.0”. The article raises the possibility that the U.S. Most Favored Nation (MFN) drug-pricing policy could contribute to delays or decisions not to launch new medicines when companies consider pricing across countries and global revenue.
It also discusses how pricing and reimbursement can prevent medicines from reaching patients even after approval, and considers the importance of clinical trial infrastructure, high-quality clinical data, and predictable pricing systems. Please read the article for our perspective.
(Reference)